Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

被引:34
作者
Garland, Suzanne M.
Steben, Marc
Hernandez-Avila, Mauricio
Koutsky, Laura A.
Wheeler, Cosette M.
Perez, Gonzalo
Harper, Diane M.
Leodolter, Sepp
Tang, Grace W. K.
Ferris, Daron G.
Esser, Mark T.
Vuocolo, Scott C.
Nelson, Micki
Railkar, Radha
Sattler, Carlos
Barr, Eliav
机构
[1] Inst Natl Sante Publ Quebec, Direct Risques Biol Environm & Occupat, Montreal, PQ H2P 1E2, Canada
[2] Royal Hosp Women, Dept Microbiol & Infect Dis, Carlton, Vic, Australia
[3] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[4] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico
[5] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[6] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA
[7] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA
[8] Natl Res Ctr, Grp Saludcoop, Bogota, Colombia
[9] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Obstet & Gynecol, Hanover, NH USA
[10] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Community & Family Med, Hanover, NH USA
[11] Med Univ Vienna, Womens Hlth Clin, Dept Gynecol & Obstet, Vienna, Austria
[12] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Peoples R China
[13] Med Coll Georgia, Dept Family Med, Augusta, GA 30912 USA
[14] Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA
[15] Merck Res Labs, West Point, PA USA
关键词
D O I
10.1128/CVI.00478-06
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The incorporation of multiple antigens into a single human papillomavirus (HPV) vaccine may induce immune interference. To evaluate whether interference occurs when HPV type 16 (HPV16) virus-like particles are combined in a multivalent vaccine, we conducted a study to evaluate anti-HPV16 responses among subjects receiving three-dose regimens of either a monovalent HPV16 vaccine or a quadrivalent HPV (types 6, 11, 16, and 18) vaccine.
引用
收藏
页码:792 / 795
页数:4
相关论文
共 13 条
  • [1] Estimates of the incidence and prevalence of sexually transmitted diseases in the United States
    Cates, W
    [J]. SEXUALLY TRANSMITTED DISEASES, 1999, 26 (04) : S2 - S7
  • [2] Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18
    Dias, D
    Van Doren, J
    Schlottmann, S
    Kelly, S
    Puchalski, D
    Ruiz, W
    Boerckel, P
    Kessler, J
    Antonello, JM
    Green, T
    Brown, M
    Smith, J
    Chirmule, N
    Barr, E
    Jansen, KU
    Esser, MT
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) : 959 - 969
  • [3] Combination vaccines consisting of acellular pertussis vaccines
    Edwards, KM
    Decker, MD
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (04) : S97 - S102
  • [4] GARLAND SM, IN PRESS N ENGL J ME
  • [5] COMPARATIVE-ANALYSIS OF 2 RATES
    MIETTINEN, O
    NURMINEN, M
    [J]. STATISTICS IN MEDICINE, 1985, 4 (02) : 213 - 226
  • [6] Epidemiologic classification of human papillomavirus types associated with cervical cancer
    Muñoz, N
    Bosch, FX
    de Sanjosé, S
    Herrero, R
    Castellsagué, X
    Shah, KV
    Snijders, PJF
    Meijer, CJLM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 518 - 527
  • [7] Glycoprotein-D-adjuvant vaccine to prevent genital herpes
    Stanberry, LR
    Spruance, SL
    Cunningham, AL
    Bernstein, DI
    Mindel, A
    Sacks, S
    Tyring, S
    Aoki, FY
    Slaoui, M
    Denis, M
    Vandepapeliere, P
    Dubin, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) : 1652 - 1661
  • [8] Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid
    Trollfors, B
    Taranger, J
    Lagergård, T
    Sundh, V
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (01) : 85 - 86
  • [9] Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
    Villa, LL
    Costa, RLR
    Petta, CA
    Andrade, RP
    Ault, KA
    Giuliano, AR
    Wheeler, CM
    Koutsky, LA
    Malm, C
    Lehtinen, M
    Skjeldestad, FE
    Olsson, SE
    Steinwall, M
    Brown, DR
    Kurman, R
    Ronnett, BM
    Stoler, MH
    Ferenczy, A
    Harper, DM
    Tamms, GM
    Yu, J
    Lupinacci, L
    Railkar, R
    Taddeo, FJ
    Jansen, KU
    Esser, MT
    Sings, HL
    Saah, AJ
    Lupinacci, L
    [J]. LANCET ONCOLOGY, 2005, 6 (05) : 271 - 278
  • [10] Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt